Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models
Inflammatory Bowel Diseases (IBD) are disorders of the gastrointestinal tract characterized by recurrent inflammation that requires lifelong treatments. Probiotic microorganisms appear as an alternative for these patients; however, probiotic characteristics are strain dependent and each probiotic ne...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2015/146972 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554488400969728 |
|---|---|
| author | Alejandra de Moreno de LeBlanc Silvina del Carmen Jean-Marc Chatel Anderson Miyoshi Vasco Azevedo Philippe Langella Luis G. Bermúdez-Humarán Jean Guy LeBlanc |
| author_facet | Alejandra de Moreno de LeBlanc Silvina del Carmen Jean-Marc Chatel Anderson Miyoshi Vasco Azevedo Philippe Langella Luis G. Bermúdez-Humarán Jean Guy LeBlanc |
| author_sort | Alejandra de Moreno de LeBlanc |
| collection | DOAJ |
| description | Inflammatory Bowel Diseases (IBD) are disorders of the gastrointestinal tract characterized by recurrent inflammation that requires lifelong treatments. Probiotic microorganisms appear as an alternative for these patients; however, probiotic characteristics are strain dependent and each probiotic needs to be tested to understand the underlining mechanisms involved in their beneficial properties. Genetic modification of lactic acid bacteria (LAB) was also described as a tool for new IBD treatments. The first part of this review shows different genetically modified LAB (GM-LAB) described for IBD treatment since 2000. Then, the two principally studied strategies are discussed (i) GM-LAB producing antioxidant enzymes and (ii) GM-LAB producing the anti-inflammatory cytokine IL-10. Different delivery systems, including protein delivery and DNA delivery, will also be discussed. Studies show the efficacy of GM-LAB (using different expression systems) for the prevention and treatment of IBD, highlighting the importance of the bacterial strain selection (with anti-inflammatory innate properties) as a promising alternative. These microorganisms could be used in the near future for the development of therapeutic products with anti-inflammatory properties that can improve the quality of life of IBD patients. |
| format | Article |
| id | doaj-art-46b598451a024246bf0c9c3c0cf4f2f8 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-46b598451a024246bf0c9c3c0cf4f2f82025-02-03T05:51:26ZengWileyGastroenterology Research and Practice1687-61211687-630X2015-01-01201510.1155/2015/146972146972Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine ModelsAlejandra de Moreno de LeBlanc0Silvina del Carmen1Jean-Marc Chatel2Anderson Miyoshi3Vasco Azevedo4Philippe Langella5Luis G. Bermúdez-Humarán6Jean Guy LeBlanc7Centro de Referencia para Lactobacilos (CERELA-CONICET), T4000ILC San Miguel de Tucumán, ArgentinaCentro de Referencia para Lactobacilos (CERELA-CONICET), T4000ILC San Miguel de Tucumán, ArgentinaINRA, Commensal and Probiotics-Host Interactions Laboratory, UMR1319 Micalis, 78350 Jouy-en-Josas, FranceFederal University of Minas Gerais (UFMG), 31270-901 Belo Horizonte, MG, BrazilFederal University of Minas Gerais (UFMG), 31270-901 Belo Horizonte, MG, BrazilINRA, Commensal and Probiotics-Host Interactions Laboratory, UMR1319 Micalis, 78350 Jouy-en-Josas, FranceINRA, Commensal and Probiotics-Host Interactions Laboratory, UMR1319 Micalis, 78350 Jouy-en-Josas, FranceCentro de Referencia para Lactobacilos (CERELA-CONICET), T4000ILC San Miguel de Tucumán, ArgentinaInflammatory Bowel Diseases (IBD) are disorders of the gastrointestinal tract characterized by recurrent inflammation that requires lifelong treatments. Probiotic microorganisms appear as an alternative for these patients; however, probiotic characteristics are strain dependent and each probiotic needs to be tested to understand the underlining mechanisms involved in their beneficial properties. Genetic modification of lactic acid bacteria (LAB) was also described as a tool for new IBD treatments. The first part of this review shows different genetically modified LAB (GM-LAB) described for IBD treatment since 2000. Then, the two principally studied strategies are discussed (i) GM-LAB producing antioxidant enzymes and (ii) GM-LAB producing the anti-inflammatory cytokine IL-10. Different delivery systems, including protein delivery and DNA delivery, will also be discussed. Studies show the efficacy of GM-LAB (using different expression systems) for the prevention and treatment of IBD, highlighting the importance of the bacterial strain selection (with anti-inflammatory innate properties) as a promising alternative. These microorganisms could be used in the near future for the development of therapeutic products with anti-inflammatory properties that can improve the quality of life of IBD patients.http://dx.doi.org/10.1155/2015/146972 |
| spellingShingle | Alejandra de Moreno de LeBlanc Silvina del Carmen Jean-Marc Chatel Anderson Miyoshi Vasco Azevedo Philippe Langella Luis G. Bermúdez-Humarán Jean Guy LeBlanc Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models Gastroenterology Research and Practice |
| title | Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models |
| title_full | Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models |
| title_fullStr | Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models |
| title_full_unstemmed | Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models |
| title_short | Current Review of Genetically Modified Lactic Acid Bacteria for the Prevention and Treatment of Colitis Using Murine Models |
| title_sort | current review of genetically modified lactic acid bacteria for the prevention and treatment of colitis using murine models |
| url | http://dx.doi.org/10.1155/2015/146972 |
| work_keys_str_mv | AT alejandrademorenodeleblanc currentreviewofgeneticallymodifiedlacticacidbacteriaforthepreventionandtreatmentofcolitisusingmurinemodels AT silvinadelcarmen currentreviewofgeneticallymodifiedlacticacidbacteriaforthepreventionandtreatmentofcolitisusingmurinemodels AT jeanmarcchatel currentreviewofgeneticallymodifiedlacticacidbacteriaforthepreventionandtreatmentofcolitisusingmurinemodels AT andersonmiyoshi currentreviewofgeneticallymodifiedlacticacidbacteriaforthepreventionandtreatmentofcolitisusingmurinemodels AT vascoazevedo currentreviewofgeneticallymodifiedlacticacidbacteriaforthepreventionandtreatmentofcolitisusingmurinemodels AT philippelangella currentreviewofgeneticallymodifiedlacticacidbacteriaforthepreventionandtreatmentofcolitisusingmurinemodels AT luisgbermudezhumaran currentreviewofgeneticallymodifiedlacticacidbacteriaforthepreventionandtreatmentofcolitisusingmurinemodels AT jeanguyleblanc currentreviewofgeneticallymodifiedlacticacidbacteriaforthepreventionandtreatmentofcolitisusingmurinemodels |